Berkkanoglu Murat, Isikoglu Mete, Aydin Donay, Ozgur Kemal
Antalya In Vitro Fertilization, Antalya, Turkey.
Fertil Steril. 2007 Sep;88(3):665-9. doi: 10.1016/j.fertnstert.2006.11.150. Epub 2007 Feb 12.
To assess the clinical effects of recombinant luteinizing hormone (LH) or low-dose recombinant human chorionic gonadotropin (hCG) supplementation administered in the midfollicular phase in microdose gonadotropin-releasing hormone analogue (GnRH-a) flare-up cycles.
Prospective randomized study.
Private infertility clinic.
PATIENT(S): A total of 170 women enrolled, with 145 women eligible for randomization.
INTERVENTION(S): After randomization, 51 patients (group A) received only 600 IU of recombinant follicle-stimulating hormone (FSH) as the control group, 46 patients (group B) received 600 IU of recombinant FSH plus daily supplementation with 75 IU of recombinant luteinizing hormone, and 48 patients (group C) received 600 IU of recombinant FSH plus daily supplementation with 75 IU of recombinant hCG.
MAIN OUTCOME MEASURE(S): Peak estradiol (E(2)) levels, days of stimulation with recombinant FSH, total recombinant FSH dosage, metaphase II oocytes retrieved, pregnancy rate (positive hCG levels), clinical pregnancy rate (positive fetal cardiac activity), and cancellation rates of stimulation and embryo transfer.
RESULT(S): The pregnancy rates were 35.1%, 27.6% and 31.2% for groups A, B, and C, respectively. Clinical pregnancy rates were 27.1%, 27.5, and 21.8% for groups A, B, and C, respectively. There were no statistically significant differences in the age, peak serum E(2) concentration, total recombinant FSH dosage, days of stimulation with recombinant FSH, total number of metaphase II oocytes retrieved, number of embryos transferred, pregnancy rates, clinical pregnancy rates, or cancellation rates of stimulation and embryo transfer among the three groups.
CONCLUSION(S): Additional exogenous LH activity in the form of either recombinant luteinizing hormone or low-dose recombinant hCG is unnecessary in microdose cycles to increase pregnancy rates.
评估在微剂量促性腺激素释放激素类似物（GnRH-a）激发周期的卵泡中期补充重组促黄体生成素（LH）或低剂量重组人绒毛膜促性腺激素（hCG）的临床效果。
前瞻性随机研究。
私立不孕不育诊所。
共纳入170名女性，其中145名女性符合随机分组条件。
随机分组后，51例患者（A组）仅接受600 IU重组促卵泡生成素（FSH）作为对照组，46例患者（B组）接受600 IU重组FSH并每日补充75 IU重组促黄体生成素，48例患者（C组）接受600 IU重组FSH并每日补充75 IU重组hCG。
雌二醇（E₂）峰值水平、重组FSH刺激天数、重组FSH总剂量、获取的中期II级卵母细胞数量、妊娠率（hCG水平阳性）、临床妊娠率（有胎儿心脏活动阳性）以及刺激和胚胎移植取消率。
A组、B组和C组的妊娠率分别为35.1%、27.6%和31.2%。A组、B组和C组的临床妊娠率分别为27.1%、27.5%和21.8%。三组在年龄、血清E₂峰值浓度、重组FSH总剂量、重组FSH刺激天数、获取的中期II级卵母细胞总数、移植胚胎数、妊娠率、临床妊娠率或刺激和胚胎移植取消率方面均无统计学显著差异。
在微剂量周期中，以重组促黄体生成素或低剂量重组hCG形式额外补充外源性LH活性对于提高妊娠率并无必要。
